This month represented an important step forward in the treatment of Alzheimer’s disease with Eli Lilly announcing the successful results of their phase III clinical trials for their monocolonal antibody (mAB) donanemab. In addition to decreasing the...
This month represented an important step forward in the treatment of Alzheimer’s disease with Eli Lilly announcing the successful results of their phase III clinical trials for their monocolonal antibody (mAB) donanemab. In addition to decreasing the...